Dr. Roychowdhury on FGFR Inhibitor Infigratinib in Cholangiocarcinoma
April 1st 2019Sameek Roychowdhury, MD, PhD, associate professor of medical oncology, the Ohio State University Comprehensive Cancer Center, discusses a phase II study with infigratinib (BGJ398) in patients with cholangiocarcinoma.
Read More